In the current economic downturn, superimposed upon the continued restructuring of the pharmaceutical industry, there is an ever increasing demand for companies to expand their externalisation and in-licensing activities, but with less time available from other internal scientific experts and departments to devote the time to supporting such activities. Outside resources are required to supplement those internal ones.
Globally companies have been very successful in recent years in overriding the ‘not-invented here’ syndrome and making huge returns on licensed in clinical programmes. As early as 1998, the contribution that in-licensed compounds made to companies’ blockbuster drug earnings was evident (see Booz Allen Hamilton data below). More than a quarter of pharma revenue comes from in-licensed products.
The trend is growing and as more and more companies compete for fewer and fewer high quality programmes, such that programmes must now be identified and in-licensed at an earlier stage; phase I or even late pre-clinical.
P2F is very happy to receive enquiries to help find new exciting pre-clinical and clinical projects from non-profit academic institutions, smalll biotech strart ups, to medium and large pharma worldwide, Our expertise is particularly suited to oncology, anti-inflammatory, CNS and dermatology.
Regesterd Company Number 7822656
|
